niacinamide has been researched along with incb-018424 in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
Cardwell, LA; Cline, A; Feldman, SR | 1 |
Xicoy, B; Zamora, L | 1 |
Georgiou, S; Plachouri, KM | 1 |
2 review(s) available for niacinamide and incb-018424
Article | Year |
---|---|
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
2 other study(ies) available for niacinamide and incb-018424
Article | Year |
---|---|
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Current treatment of myeloproliferative neoplasias: three scenarios.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Niacinamide; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Thrombocythemia, Essential; Time Factors; Withholding Treatment | 2020 |